

Dragon, Karen E. (CDC/NIOSH/EID)

From:
Sent: Thursday, September 06, 2007 12:17 PM
To: NIOSH Docket Office (CDC)
Subject: 105 - HazDrug Update Comments

Attachments: Copy of PublicReviewForm2006-05-01-07.xls; disclaimer.txt



Copy of
licReviewForm2006



disclaimer.txt (587
B)

Drugs to Review 2006 Docket #NIOHS-105
 Reviewer : Catherine Benham
 Affiliation :

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Abilify	aripiprazole			
Alimta	pemetrexed			
Amevive	alfacept			
Amitiza	lubiprostone	x		liquid gel capsules. Unlikely exposure on routine administration
Apokyn	apomorphine HCl			
Arranon	nelarabine			
Avastin	bevacizumab			
Azilect	rasagiline mesylate			
Baraclude	entecavir			
Chantix	varenicline			
Clolar	clofarabine			film coated tabs. Unlikely exposure on routine administration
Cordarone	amiodarone HCl			
Dacogen	decitabine			
Depacone	valproate Na			
Depakene	valproic acid			
Depakote	divalproex Na			liquid gel capsules. Unlikely exposure on routine administration
Depo-Provera**	medroxyprogesterone acetate			film coated tabs. Unlikely exposure on routine administration
Elidel	pimecrolimus			
Erbitux	cetuximab			
Geodon	ziprasidone			
Gleevec	imatinib mesylate			
Hivid	zalcitabine			
Hycamtin	topotecan HCl			

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer : Catherine Benham

Affiliation :

Send reviews to: niocindocket@cdc.gov

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Increlex	mecasermin (rDNA origin)			
Kepivance	palifermin			
Leustatin	ciadrabine			
Lunesta	eszopiclone			film coated tabs. Unlikely exposure on routine administration
Lyrica	pregabalin			
Metastron	strontium-89 chloride			
Mycamine	micalfungin sodium			
Myozyme	alglucosidase alfa			
Nexavar	sorafenib			
Orencia	abatacept			
Paxil	paroxetine HCl			film coated tabs. Unlikely exposure on routine administration
Pentetate Calcium				
Trisodium				
Photofrin	porfimer sodium			
Provera**	medroxyprogesterone acetate			
Quadramet	samarium 153 lexitronam			
Rapamune	sirolimus			
Revlimid	lenalidomide			
Risperdal Consta**	risperdone			
Risperdal**	risperidone			
Rituxan	rituximab			
Rozerem	ramelteon			film coated tabs. Unlikely exposure on routine administration
Seroquel	quetiapine fumerate			film coated tabs. Unlikely exposure on routine administration

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer : Catherine Benham

Affiliation :

Send reviews to: niocindocket@cdc.gov

Proprietary Name	Established Name	Should this Drug be Included in the NIOSH Hazardous Drugs List ?		Comments
		yes	no	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Spiriva Handihaler	tiotropium bromide			
Sprycel	dasatinib			
Sustiva	efavirenz			
Sutent	sunitinib malate			
Tarceva	erlotinib HCl			
Tindamax	tinidazole			
Tracleer	bosentan			
Trileptal	oxcarbazepine			
Tygacil	tigecycline			
Tysabri	natalizumab			
Velcade	bortizomib			
Vidaza	azacitidine			
Viramune	nevirapine			
Viread	tenofovir			
Vision Blue	trypan blue			
Zolinza	vorinostat			
Zonegran	zonisamide			
New FDA Drugs and Warnings Not Fitting NIOSH Criteria For Hazardous Drugs				
Actoplus Met	pioglitazone HCl/ metroformin HCl			
Actos	pioglitazone HCl			
Adderall	amphetamines			

film coated tabs. Unlikely exposure on routine administration

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer : Catherine Benham

Affiliation :

Send reviews to: niocindocket@cdc.gov

<u>Proprietary Name</u>	<u>Established Name</u>	<u>Should this Drug be Included in the NIOSH Hazardous Drugs List ?</u>		<u>Comments</u>
		<u>yes</u>	<u>no</u>	

New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs

Amphadase**	hyaluronidase			
Apidra	insulin glulisine			
Aptivus	tipranavir			
Aranesp	darbeoetin alfa			
Avandaryl	rosiglitazone maleate/ glimepiride			
Avonex	interferon beta 1a			
Betaseron	interferon beta 1b			
Byetta	exenatide			
Campral	acamprosate calcium			
Candidis	caspofungin acetate			
ChiRhoStim	human secretion			
Clozaril	clozapine			
Concerta*	methylphenidate HCl			
Cymbalta	duloxetine HCl			
Daytrana*	methylphenidate HCl			
Dexedrine	dextroamphetamine			
Dilaudid	hydromorphone HCl			
Diovan	valsartan			
Elaprase	idursulfate			
Elmiron	pentosan polysulfate Na			
Enablex	darifenacin HBr			
Epogen**	epoetin alfa			

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer : Catherine Benham

Affiliation :

Send reviews to: niocindocket@cdc.gov

<u>Proprietary Name</u>	<u>Established Name</u>	<u>Should this Drug be Included in the NIOSH Hazardous Drugs List ?</u>		<u>Comments</u>
		<u>yes</u>	<u>no</u>	

New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs

Eraxis	andulafungin			
Ethylol	amifostine			
Exjade	deferasirox			
Focalin	dexmethyphenidate HCl			
Fortovase**	saquinavir mesylate			
Fosrenol	lanthanum carbonate hydrate			
Gabitril	tiagabine			
Herceptin	trastuzumab			
Humira	adalimumab			
Hydase**	hyaluronidase			
Invirase**	saquinavir mesylate			
Iplex	mecasermin rinfabate			
Januvia	sitagliptin phosphate			
Ketek	telithromycin			
Lamictal	lamotrigine			
Levemir	insulin detemir			
Lucentis	ranibizumab			
Lumigan	bimatoprost			
Macugen	pegaptanib sodium			
Magnevist	gadopentetate dimeglumine			
Metadate*	methylphenidate HCl			
Methylin*	methylphenidate HCl			
Multihance	gadobenate dimeglumine			

Drugs to Review 2006 Docket #NIOOSH-105

Reviewer : Catherine Benham

Affiliation :

Send reviews to: niocindocket@cdc.gov

<u>Proprietary Name</u>	<u>Established Name</u>	<u>Should this Drug be Included in the NIOSH Hazardous Drugs List ?</u>		<u>Comments</u>
		<u>yes</u>	<u>no</u>	

New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs

Naglazyme	galsulfase			
Nevanac	nepafenac			
Nexium	esomeprazole magnesium			
Noxafil	posaconazole			
NutreStore	L-glutamine			
Omacor	omega-3-acid ethylesters			
Opana	oxymorphone HCl			
Pentetate Zinc				
Trisodium				
Prevacid NapralPAC	lansoprazole; naproxen			
Prezista	darunavir			
Prialt	ziconotide			
Procrit**	epoetin alfa			
Propranolol HCl				
Ranexa	ranolazine			
Raptiva	efalizumab			
Remicade	infliximab			
Ritalin*	methylphenidate HCl			
Sanctura	tropium chloride			
Sensipar	cinacalcet HCl			
Serzone	nefazodone HCl			
Strattera	atomoxetine HCl			
Symlin	pramlintide acetate			

Drugs to Review 2006 Docket #NIOSH-105
 Reviewer : Catherine Benham
 Affiliation :

Send reviews to: niocindocket@cdc.gov

<u>Proprietary Name</u>	<u>Established Name</u>	<u>Should this Drug be Included in the NIOSH Hazardous Drugs List ?</u>		<u>Comments</u>
		<u>yes</u>	<u>no</u>	
New FDA Drugs and Warnings Fitting NIOSH Criteria For Hazardous Drugs				
Trasylol	aprotinin			
Tyzeka	telbivudine			
Vectibix	panitumumab			
Ventavis	iloprost			
Veregen	kunecatechins			
VESicare	solifenacin succinate			
Videx	didanosine			
Visudyne	verteporfin			
Vitrase	ovine hyaluronidase			
Wellbutrin**	bupropion HCl			
Xifaxan	rifaximin			
Zarontin	ethosuximide			
Zinecard	dextrazoxane			
Zyban**	bupropion HCl			
Zyprexa	olanzapine			

* = several proprietary names for same drug; ** = two proprietary names for same drug

ADDITIONAL COMMENTS

Thought process included how harmful would this be to the average working professional dispensing or administering this medication routinely. Exposure rate should be low on coated tablets, sealed gelatin capsules, etc.